Anixa Biosciences (ANIX) Non-Current Assets (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Non-Current Assets came in at $173000.0 in Q2 2026, down 18.01% YoY from $211000.0 in Q2 2025, and down 10.36% on a QoQ basis from $193000.0 in Q4 2025.
Anixa Biosciences (ANIX) Non-Current Assets (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Non-Current Assets data on file, last reported at $173000.0 in Q2 2026.
- Quarterly Non-Current Assets fell 18.01% year-over-year to $173000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $779000.0 (down 13.25% YoY) and the FY2025 annual result came in at $193000.0, down 15.72% from the prior year.
- Non-Current Assets fell to $173000.0 in Q2 2026, from $193000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $244000.0 in Q1 2022 to a low of $141000.0 in Q2 2024.
- A 5-year average of $200411.8 and a median of $202000.0 in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 2041.97% — and 2024, when it dropped 25.4%.
- Tracing ANIX's Non-Current Assets over 5 years: stood at $212000.0 in 2022, then dropped by 21.7% to $166000.0 in 2023, then soared by 37.95% to $229000.0 in 2024, then fell by 15.72% to $193000.0 in 2025, then fell by 10.36% to $173000.0 in 2026.
- The last three Non-Current Assets figures came in at $173000.0 (Q2 2026), $193000.0 (Q4 2025), and $202000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | 173,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 173,000.00 |
| Oct 31, 2025 | 193,000.00 |
| Jul 31, 2025 | 202,000.00 |
| Apr 30, 2025 | 211,000.00 |
| Jan 31, 2025 | 220,000.00 |
| Oct 31, 2024 | 229,000.00 |
| Jul 31, 2024 | 238,000.00 |
| Apr 30, 2024 | 141,000.00 |
| Jan 31, 2024 | 153,000.00 |
| Oct 31, 2023 | 166,000.00 |
| Jul 31, 2023 | 178,000.00 |
| Apr 30, 2023 | 189,000.00 |
| Jan 31, 2023 | 201,000.00 |
| Oct 31, 2022 | 212,000.00 |
| Jul 31, 2022 | 223,000.00 |
| Apr 30, 2022 | 234,000.00 |
| Jan 31, 2022 | 244,000.00 |
| Oct 31, 2021 | 254,000.00 |
| Jul 31, 2021 | 10,411.00 |
| Apr 30, 2021 | 25,574.00 |